Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy

被引:161
作者
Dore, GJ
McDonald, A
Li, YM
Kaldor, JM
Brew, BJ
机构
[1] Univ New S Wales, Natl Ctr HIV Epidemiol & Clin Res, Darlinghurst, NSW 2010, Australia
[2] St Vincents Hosp, HIV Immunol Infect Dis Clin Serv Unit, Sydney, NSW 2010, Australia
[3] St Vincents Hosp, Dept Neurol, Sydney, NSW 2010, Australia
关键词
HIV; AIDS dementia complex; antiretroviral therapy;
D O I
10.1097/00002030-200307040-00015
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To determine the effect of introduction of highly active antiretroviral therapy (HAART) on survival following AIDS dementia complex (ADC). Methods: Australian AIDS notification data in the period 1993-2000 were examined. In order to examine the impact of HAART, two periods of AIDS diagnoses were chosen: pre-HAART (1993-1995) and HAART (1996-2000). Median survival was based on Kaplan-Meier estimates, with examination of factors influencing survival in a Cox proportional hazards model. Results: In the period 1993-2000 in Australia, 5017 initial AIDS illnesses were diagnosed among 4351 AIDS patients. The proportion of AIDS cases with ADC increased from 5.2% in 1993-1995 to 6.8% in 1996-2000 (P=0.029). Median survival following AIDS increased from 19.6 months for those diagnosed with AIDS in 1993-1995 to 39.6 months for those diagnosed in 1996-2000 (P < 0.0005). Median survival following ADC increased to a greater extent than that for all other AIDS illnesses, from 11.9 months in 1993-1995 to 48.2 in 1996-2000 (P < 0.0005). Most striking was the increase in survival among those with ADC and a CD4 cell count < 100 x 10(6) cells/l at diagnosis; 5.1 months in 1993-1995 to 38.5 months in 1996-2000 (P < 0.0005). Conclusion: Although there has been a proportional increase in ADC at AIDS diagnosis, survival following ADC has improved markedly in the era of HAART. (C) 2003 Lippincott Williams Wilkins.
引用
收藏
页码:1539 / 1545
页数:7
相关论文
共 44 条
[1]   Incidence and risk factors for toxoplasmic encephalitis in human immunodeficiency virus-infected patients before and during the highly active antiretroviral therapy era [J].
Abgrall, S ;
Rabaud, C ;
Costagliola, D .
CLINICAL INFECTIOUS DISEASES, 2001, 33 (10) :1747-1755
[2]  
[Anonymous], 1999, MMWR Recomm Rep, V48, P1
[3]  
[Anonymous], 1996, Lancet, V348, P283
[4]  
[Anonymous], 1992, MMWR-MORBID MORTAL W, V41, P1
[5]  
*AUSTR NAT COUNC A, 1994, ANCA B, V18, P1
[6]   Variable progression of HIV-associated dementia [J].
Bouwman, FH ;
Skolasky, RL ;
Hes, D ;
Selnes, OA ;
Glass, JD ;
Nance-Sproson, TE ;
Royal, W ;
Dal Pan, GJ ;
McArthur, JC .
NEUROLOGY, 1998, 50 (06) :1814-1820
[7]   Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy [J].
Brodt, HR ;
Kamps, BS ;
Gute, P ;
Knupp, B ;
Staszewski, S ;
Helm, EB .
AIDS, 1997, 11 (14) :1731-1738
[8]  
*CDCP, 1987, MMWR-MORBID MORTAL W, V36, pS3
[9]   Impact of opportunistic disease on survival in patients with HIV infection [J].
Chaisson, RE ;
Gallant, JE ;
Keruly, JC ;
Moore, RD .
AIDS, 1998, 12 (01) :29-33
[10]   Differential impact of combined antiretroviral therapy on the survival of Italian patients with specific AIDS-defining illnesses [J].
Conti, S ;
Masocco, M ;
Pezzotti, P ;
Toccaceli, V ;
Vichi, M ;
Boros, S ;
Urciuoli, R ;
Valdarchi, C ;
Rezza, G .
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2000, 25 (05) :451-458